Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Select Medical Holdings Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.45 (market cap $8.04B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.9× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SEM | |
|---|---|---|
Market Cap | $8.04B | $2.05B |
Sector | Health | Health |
52-Week High | $339.75 | $16.66 |
52-Week Low | $241.71 | $11.77 |
Enterprise Value | $7.85B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. announced on June 30, 2026. The stock shows mixed signals with a bullish overall technical outlook but bearish moving averages, while fundamentals indicate modest profitability with a net income margin of 2.42% and a P/E ratio of 15.43. Recent earnings have been inconsistent, with Q1 2026 missing expectations.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into board fiduciary duties posing reputational risks. Analyst sentiment is neutral with a 57.15% hold rating, reflecting uncertainty post-buyout. Investors face limited growth prospects amid stable revenues and margin pressures, emphasizing caution in the current holding pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
